Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Dec 15;16(1):10–39. doi: 10.1038/s44321-023-00003-z

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. Creative Commons Public Domain Dedication waiver http://creativecommons.org/publicdomain/zero/1.0/ applies to the data associated with this article, unless otherwise stated in a credit line to the data, but does not extend to the graphical or creative elements of illustrations, charts, or figures. This waiver removes legal barriers to the re-use and mining of research data. According to standard scholarly practice, it is recommended to provide appropriate citation and attribution whenever technically possible.

PMC Copyright notice

Figure EV5 — (A) MYSM1 and CCND1 protein expression in the “Responders” and “Non-responders” samples before and after AI treatment were examined by western blot. “B” represents cases before AI treatment, “A” represents cases after AI treatment (n = 6). (B, E) Growth curve showing the effect of MYSM1 knockdown on MCF-7 cell proliferation with Fulverstrant (200 nM) (B) or Letrozole (100 nM) (E) treatment. Total cell viability was assessed every other day by MTS assay. (C, F) A cellular viability detection in MYSM1-deletion MCF-7 cells that incubated in various concentrations of Fulverstrant (C) or Letrozole (F) for 7 days. (D, G) MCF-7 cells with/without MYSM1 knockdown were subjected to colony formation assay under diverse doses of Fulverstrant (D) or Letrozole (G). Clones were stained with R250 and photographed 2 weeks later. (H, K) The line chart renders the relative proliferation of the shMYSM1 group compared to the shCtrl group in BT474 (H) or T47D TMR (K) cells in the stimulation of Tamoxifen (1 μM) or not. (I, L) The panels show colony-formation assay conducted in BT474 (I) or T47D TMR (L) cells infected with lentivirus expressing shCtrl/shMYSM1. Cells in each panel were treated with different doses of Tamoxifen for 15 days before fixation and R250 staining. (J) Western blot assay detecting MYSM1 protein expression in MCF-7, T47D, and their corresponding Tamoxifen-resistant (TMR) cells. Data information: *P < 0.05, **P < 0.01, ***P < 0.001 (mean ± SD; Student’s t test; n = 3 independent experiments).